You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The test for cervical cancer screening previously received the IVD mark and US Food and Drug Administration approval on the Cobas 4800 system.
The test will be developed in Global Good labs and ported onto QuantuMDx's handheld molecular platform.
In Nature this week: Plasmodium genomes and evolution, novel developmental disorder loci, and more.
The Cancer Genome Atlas Research Network team uncovered new mutations and amplifications in their cohort of primary cervical cancers.
The firms will target 18 Latin American countries in three years, with the goal of creating a complete HPV diagnostics system for the region.
The firm is also pursuing ovarian cancer screening and head and neck cancer tests using methylation-specific PCR.
The firm's PCR-based products for HPV-associated cancers look at DNA methylation at specific genes and include several sample preparation kits.
An evaluation of more than 5,000 women attending primary cervical cancer screening showed self-collection and physician-collected samples are comparable.
The UK firm anticipates CE marking shortly and will focus on the European and Chinese markets for its multiplex PCR test for human papillomavirus genotyping.
The company's Confidence assays are designed to detect if a woman has a high-risk HPV subtype and, if so, determine her risk of developing cervical pre-cancer or cancer.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.